Other Species / Isoforms
  Wee1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
R14-m1
QQPPPPRrAGAACTL
0 1
Wee1 (human) QQPPPPRrAGAACTL R14-m1
Wee1 (mouse) QQPPPTRRVGAAysL R14
Wee1 (rat) QQPPPTRRAAAACSL R14
Wee1 (frog) gap -
C19
PRrAGAACTLRQKLI
0 8
Wee1 (human) PRrAGAACTLRQKLI C19
Wee1 (mouse) TRRVGAAysLRQKLI Y19-p
Wee1 (rat) TRRAAAACSLRQKLI C19
Wee1 (frog) gap -
T20
RrAGAACTLRQKLIF
0 2
Wee1 (human) RrAGAACTLRQKLIF T20
Wee1 (mouse) RRVGAAysLRQKLIF S20-p
Wee1 (rat) RRAAAACSLRQKLIF S20
Wee1 (frog) gap -
S48-p
EEEGSGHstGEDsAF
0 1
Wee1 (human) EEEGSGHstGEDsAF S48-p
Wee1 (mouse) EEEGSGHSTGEDSAF S47
Wee1 (rat) EEEGSGHSTGEDSAF S47
Wee1 (frog) gap -
T49-p
EEGSGHstGEDsAFQ
0 1
Wee1 (human) EEGSGHstGEDsAFQ T49-p
Wee1 (mouse) EEGSGHSTGEDSAFQ T48
Wee1 (rat) EEGSGHSTGEDSAFQ T48
Wee1 (frog) gap -
S53-p
GHstGEDsAFQEPDS
Upstream
Downstream
4 1
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • PLK1 (human)
Regulatory protein:
  • CK2B (human)
Wee1 (human) GHstGEDsAFQEPDS S53-p
Wee1 (mouse) GHSTGEDSAFQEPDS S52
Wee1 (rat) GHSTGEDSAFQEPDS S52
Wee1 (frog) gap -
S67-p
SPLPPARsPtEPGPE
1 4
Wee1 (human) SPLPPARsPtEPGPE S67-p
Wee1 (mouse) SPLPSARSPAEAEAE S66
Wee1 (rat) SPLPSARSPAEAEAE S66
Wee1 (frog) gap -
T69-p
LPPARsPtEPGPERR
0 3
Wee1 (human) LPPARsPtEPGPERR T69-p
Wee1 (mouse) LPSARSPAEAEAERR A68
Wee1 (rat) LPSARSPAEAEAERR A68
Wee1 (frog) gap -
S78-p
PGPERRRsPGPAPGs
0 3
Wee1 (human) PGPERRRsPGPAPGs S78-p
Wee1 (mouse) EAERRRRSPGAEPSS S78
Wee1 (rat) EAERRRRsPGAEPss S78-p
Wee1 (frog) gap -
G84
RsPGPAPGsPGELEE
0 1
Wee1 (human) RsPGPAPGsPGELEE G84
Wee1 (mouse) RSPGAEPSSPGELED S84
Wee1 (rat) RsPGAEPssPGELEE S84-p
Wee1 (frog) gap -
S85-p
sPGPAPGsPGELEED
0 3
Wee1 (human) sPGPAPGsPGELEED S85-p
Wee1 (mouse) SPGAEPSSPGELEDD S85
Wee1 (rat) sPGAEPssPGELEED S85-p
Wee1 (frog) gap -
S121-p
WEEEGFGsSsPVKsP
Upstream
Downstream
2 0
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Kinase, in vitro:
  • CK2A1 (human)
Regulatory protein:
  • CK2B (human)
Treatment
  • TBB
Wee1 (human) WEEEGFGsSsPVKsP S121-p
Wee1 (mouse) WEEEGFGSSSPVKSP S121
Wee1 (rat) WEEEGFGSSSPVKsP S121
Wee1 (frog) gap -
S123-p
EEGFGsSsPVKsPAA
Upstream
Downstream
3 0
Effects on Modified Protein
  • molecular association, regulation
  • phosphorylation
  • protein degradation
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • CDK1 (human)
Phosphatases, in vitro:
  • CDC14A (human)
Putative upstream phosphatases:
  • CDC14A (human)
Treatment
  • cycloheximide
  • siRNA
Wee1 (human) EEGFGsSsPVKsPAA S123-p
Wee1 (mouse) EEGFGSSSPVKSPST S123
Wee1 (rat) EEGFGSSSPVKsPTT S123
Wee1 (frog) gap -
S127-p
GsSsPVKsPAAPyFL
Upstream
0 13
Treatment
  • dasatinib
Wee1 (human) GsSsPVKsPAAPyFL S127-p
Wee1 (mouse) GSSSPVKSPSTAYFL S127
Wee1 (rat) GSSSPVKsPTTAYFL S127-p
Wee1 (frog) gap -
Y132-p
VKsPAAPyFLGSsFs
Upstream
0 20
Treatment
  • FGF2
  • HGF
Wee1 (human) VKsPAAPyFLGSsFs Y132-p
Wee1 (mouse) VKSPSTAYFLSSPFs Y132
Wee1 (rat) VKsPTTAYFLGSSFs Y132
Wee1 (frog) gap -
S137-p
APyFLGSsFsPVRCG
Upstream
0 3
Treatment
  • MG132_withdrawal
Wee1 (human) APyFLGSsFsPVRCG S137-p
Wee1 (mouse) TAYFLSSPFsPVRCG P137
Wee1 (rat) TAYFLGSSFsPVRCG S137
Wee1 (frog) gap -
S139-p
yFLGSsFsPVRCGGP
Upstream
Downstream
1 29
Effects on Modified Protein
  • molecular association, regulation
  • phosphorylation
  • protein degradation
Effects on Biological Processes:
  • cell cycle regulation
Phosphatases, in vitro:
  • CDC14A (human)
Putative in vivo kinases:
  • CDK1 (human)
Putative upstream phosphatases:
  • CDC14A (human)
Treatment
  • cycloheximide
  • EGF
  • purvalanol
  • siRNA
Wee1 (human) yFLGSsFsPVRCGGP S139-p
Wee1 (mouse) YFLSSPFsPVRCGGP S139-p
Wee1 (rat) YFLGSSFsPVRCGGP S139-p
Wee1 (frog) gap -
S150-p
CGGPGDAsPRGCGAR
Upstream
0 11
Treatment
  • MG132_withdrawal
Wee1 (human) CGGPGDAsPRGCGAR S150-p
Wee1 (mouse) CGGPGDASPQGCGAP S150
Wee1 (rat) CGGPGDASPRGCGVP S150
Wee1 (frog) gap -
S165-p
RAGEGRRsPRPDHPG
Upstream
1 33
Treatment
  • dasatinib
Wee1 (human) RAGEGRRsPRPDHPG S165-p
Wee1 (mouse) RAMDDPCsPQPDyPs S165-p
Wee1 (rat) RAMDDPCSPQPDYPS S165
Wee1 (frog) gap -
H170
RRsPRPDHPGtPPHK
0 11
Wee1 (human) RRsPRPDHPGtPPHK H170
Wee1 (mouse) PCsPQPDyPstPPHK Y170-p
Wee1 (rat) PCSPQPDYPSTPPHK Y170
Wee1 (frog) gap -
G172
sPRPDHPGtPPHKTF
0 2
Wee1 (human) sPRPDHPGtPPHKTF G172
Wee1 (mouse) sPQPDyPstPPHKTF S172-p
Wee1 (rat) SPQPDYPSTPPHKTF S172
Wee1 (frog) gap -
T173-p
PRPDHPGtPPHKTFR
Upstream
1 31
Treatment
  • dasatinib
Wee1 (human) PRPDHPGtPPHKTFR T173-p
Wee1 (mouse) PQPDyPstPPHKTFR T173-p
Wee1 (rat) PQPDYPSTPPHKTFR T173
Wee1 (frog) VGAECPGTPLHYSTW T86
T187-p
RKLRLFDtPHtPKsL
0 11
Wee1 (human) RKLRLFDtPHtPKsL T187-p
Wee1 (mouse) RKLRLFDtPHtPKSL T187-p
Wee1 (rat) RKLRLFDTPHTPKSL T187
Wee1 (frog) KKLKLCDTPYTPKSL T101
T190-p
RLFDtPHtPKsLLsK
0 19
Wee1 (human) RLFDtPHtPKsLLsK T190-p
Wee1 (mouse) RLFDtPHtPKSLLSK T190-p
Wee1 (rat) RLFDTPHTPKSLLSK T190
Wee1 (frog) KLCDTPYTPKSLLYK T104
S193-p
DtPHtPKsLLsKArG
0 2
Wee1 (human) DtPHtPKsLLsKArG S193-p
Wee1 (mouse) DtPHtPKSLLSKARV S193
Wee1 (rat) DTPHTPKSLLSKARV S193
Wee1 (frog) DTPYTPKSLLYKTLP S107
S196-p
HtPKsLLsKArGIDS
0 2
Wee1 (human) HtPKsLLsKArGIDS S196-p
Wee1 (mouse) HtPKSLLSKARVIDS S196
Wee1 (rat) HTPKSLLSKARVIDS S196
Wee1 (frog) YTPKSLLYKTLPSPG Y110
R199-m1
KsLLsKArGIDSSSV
0 2
Wee1 (human) KsLLsKArGIDSSSV R199-m1
Wee1 (mouse) KSLLSKARVIDSGSV R199
Wee1 (rat) KSLLSKARVIDSSSV R199
Wee1 (frog) KSLLYKTLPSPGSRV L113
K207-ub
GIDSSSVkLRGssLF
0 1
Wee1 (human) GIDSSSVkLRGssLF K207-ub
Wee1 (mouse) VIDSGSVKLRGSSLF K207
Wee1 (rat) VIDSSSVKLRGSSLF K207
Wee1 (frog) under review -
S211-p
SSVkLRGssLFMDtE
Upstream
Downstream
1 2
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Kinase, in vitro:
  • GSK3B (human)
Wee1 (human) SSVkLRGssLFMDtE S211-p
Wee1 (mouse) GSVKLRGSSLFMDTE S211
Wee1 (rat) SSVKLRGSSLFMDTE S211
Wee1 (frog) SRVHCRGQRLLRFVA Q125
S212-p
SVkLRGssLFMDtEK
Upstream
Downstream
1 2
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Kinase, in vitro:
  • CK1D (human)
Wee1 (human) SVkLRGssLFMDtEK S212-p
Wee1 (mouse) SVKLRGSSLFMDTEK S212
Wee1 (rat) SVKLRGSSLFMDTEK S212
Wee1 (frog) RVHCRGQRLLRFVAG R126
T217-p
GssLFMDtEKSGKRE
1 2
Wee1 (human) GssLFMDtEKSGKRE T217-p
Wee1 (mouse) GSSLFMDTEKSGKRE T217
Wee1 (rat) GSSLFMDTEKSGKRE T217
Wee1 (frog) GQRLLRFVAGTGAEL V131
T239-p
QVNINPFtPDsLLLH
Upstream
Downstream
2 0
Effects on Modified Protein
  • enzymatic activity, inhibited
  • phosphorylation
Effects on Biological Processes:
  • cell cycle regulation
Regulatory protein:
  • CDK2 (human)
  • CTDP1 (human)
Treatment
  • nocodazole
Wee1 (human) QVNINPFtPDsLLLH T239-p
Wee1 (mouse) QVNINPFTPDPVLLH T239
Wee1 (rat) QVNINPFTPDPVMLH T239
Wee1 (frog) LVNINPFTPESYRQT T150
S242-p
INPFtPDsLLLHSSG
1 1
Wee1 (human) INPFtPDsLLLHSSG S242-p
Wee1 (mouse) INPFTPDPVLLHSSG P242
Wee1 (rat) INPFTPDPVMLHSSG P242
Wee1 (frog) INPFTPESYRQTHFQ S153
Y258-p
CRRRKRTyWNDsCGE
0 1
Wee1 (human) CRRRKRTyWNDsCGE Y258-p
Wee1 (mouse) CRGRKRAYFNDSSED Y258
Wee1 (rat) CRGRKRAYFNDSSED Y258
Wee1 (frog) NGKRKERPEDDCRTD P169
S262-p
KRTyWNDsCGEDMEA
0 2
Wee1 (human) KRTyWNDsCGEDMEA S262-p
Wee1 (mouse) KRAYFNDSSEDMEAs S262
Wee1 (rat) KRAYFNDSSEDMEAS S262
Wee1 (frog) KERPEDDCRTDRQMK C173
S270-p
CGEDMEAsDyELEDE
0 8
Wee1 (human) CGEDMEAsDyELEDE S270-p
Wee1 (mouse) SSEDMEAsDYEFEDE S269-p
Wee1 (rat) SSEDMEASDYEFEDE S269
Wee1 (frog) RTDRQMKYAEKEHPA Y181
Y272-p
EDMEAsDyELEDETR
0 2
Wee1 (human) EDMEAsDyELEDETR Y272-p
Wee1 (mouse) EDMEAsDYEFEDETR Y271
Wee1 (rat) EDMEASDYEFEDETR Y271
Wee1 (frog) DRQMKYAEKEHPAVF E183
K292-ub
TITESNMksRYTTEF
0 2
Wee1 (human) TITESNMksRYTTEF K292-ub
Wee1 (mouse) TITESNMKSRYTTEF K291
Wee1 (rat) TITESNMKSRYTTEF K291
Wee1 (frog) VLRETNMGSRYKTEF G203
S293-p
ITESNMksRYTTEFH
0 1
Wee1 (human) ITESNMksRYTTEFH S293-p
Wee1 (mouse) ITESNMKSRYTTEFH S292
Wee1 (rat) ITESNMKSRYTTEFH S292
Wee1 (frog) LRETNMGSRYKTEFL S204
K304-ub
TEFHELEkIGsGEFG
0 1
Wee1 (human) TEFHELEkIGsGEFG K304-ub
Wee1 (mouse) TEFHELEKIGSGEFG K303
Wee1 (rat) TEFHELEKIGSGEFG K303
Wee1 (frog) TEFLEIEKIGAGEFG K215
S307-p
HELEkIGsGEFGsVF
0 2
Wee1 (human) HELEkIGsGEFGsVF S307-p
Wee1 (mouse) HELEKIGSGEFGSVF S306
Wee1 (rat) HELEKIGSGEFGSVF S306
Wee1 (frog) LEIEKIGAGEFGSVF A218
S312-p
IGsGEFGsVFkCVKR
1 6
Wee1 (human) IGsGEFGsVFkCVKR S312-p
Wee1 (mouse) IGSGEFGSVFKCVKR S311
Wee1 (rat) IGSGEFGSVFKCVKR S311
Wee1 (frog) IGAGEFGSVFKCIKR S223
K315-ub
GEFGsVFkCVKRLDG
0 1
Wee1 (human) GEFGsVFkCVKRLDG K315-ub
Wee1 (mouse) GEFGSVFKCVKRLDG K314
Wee1 (rat) GEFGSVFKCVKRLDG K314
Wee1 (frog) GEFGSVFKCIKRLDG K226
S444-p
TSIPNAAsEEGDEDD
1 1
Wee1 (human) TSIPNAAsEEGDEDD S444-p
Wee1 (mouse) TSIPNAVSEEGDEDD S443
Wee1 (rat) TSIPNAVSEEGDEDD S443
Wee1 (frog) KQTELGQEESDGEDD E355
K460-ub
ASNKVMFkIGDLGHV
0 1
Wee1 (human) ASNKVMFkIGDLGHV K460-ub
Wee1 (mouse) ISNKVMFKIGDLGHV K459
Wee1 (rat) ISNKVMFKIGDLGHV K459
Wee1 (frog) SSGSVLYKIGDLGHV K371
S472-p
GHVTRISsPQVEEGD
1 1
Wee1 (human) GHVTRISsPQVEEGD S472-p
Wee1 (mouse) GHVTRISSPQVEEGD S471
Wee1 (rat) GHVTRISSPQVEEGD S471
Wee1 (frog) GHVTSILNPQVEEGD N383
S480-p
PQVEEGDsRFLANEV
0 1
Wee1 (human) PQVEEGDsRFLANEV S480-p
Wee1 (mouse) PQVEEGDSRFLANEV S479
Wee1 (rat) PQVEEGDSRFLANEV S479
Wee1 (frog) PQVEEGDSRFLANEI S391
K547-ub
QEFTELLkVMIHPDP
0 1
Wee1 (human) QEFTELLkVMIHPDP K547-ub
Wee1 (mouse) QEVTELLRVMIHPDP R546
Wee1 (rat) QELTELLKVMIHPDP K546
Wee1 (frog) under review -
S571-p
VKHSVLLsASRKsAE
0 1
Wee1 (human) VKHSVLLsASRKsAE S571-p
Wee1 (mouse) VKHSVLLSASRKSAE S570
Wee1 (rat) VKHSVLLSASRKSAE S570
Wee1 (frog) AKNSVLRRCVGKAAQ R482
S576-p
LLsASRKsAEQLRIE
0 2
Wee1 (human) LLsASRKsAEQLRIE S576-p
Wee1 (mouse) LLSASRKSAEQLRIE S575
Wee1 (rat) LLSASRKSAEQLRIE S575
Wee1 (frog) LRRCVGKAAQLQKQL A487
K588-ub
RIELNAEkFkNSLLQ
0 1
Wee1 (human) RIELNAEkFkNSLLQ K588-ub
Wee1 (mouse) RIELNAEKFKNSLLQ K587
Wee1 (rat) RIELNAEKFKNSLLQ K587
Wee1 (frog) under review -
K590-ub
ELNAEkFkNSLLQkE
0 1
Wee1 (human) ELNAEkFkNSLLQkE K590-ub
Wee1 (mouse) ELNAEKFKNSLLQKE K589
Wee1 (rat) ELNAEKFKNSLLQKE K589
Wee1 (frog) under review -
K590-sm
ELNAEkFkNSLLQkE
0 1
Wee1 (human) ELNAEkFkNSLLQkE K590-sm
Wee1 (mouse) ELNAEKFKNSLLQKE K589
Wee1 (rat) ELNAEKFKNSLLQKE K589
Wee1 (frog) QLNVEKFKTAMLERE K500
K596-ub
FkNSLLQkELKkAQM
0 1
Wee1 (human) FkNSLLQkELKkAQM K596-ub
Wee1 (mouse) FKNSLLQKELKKAQM K595
Wee1 (rat) FKNSLLQKELKkAQM K595
Wee1 (frog) under review -
K600-ub
LLQkELKkAQMAKAA
0 2
Wee1 (human) LLQkELKkAQMAKAA K600-ub
Wee1 (mouse) LLQKELKKAQMAAKV K599
Wee1 (rat) LLQKELKkAQMAAkV K599-ub
Wee1 (frog) MLERELKAAKLAQTS A510
K605
LKkAQMAKAAAEERA
0 1
Wee1 (human) LKkAQMAKAAAEERA K605
Wee1 (mouse) KKAQMAAKVAAEERA K605
Wee1 (rat) KkAQMAAkVAAEERA K605-ub
Wee1 (frog) KAAKLAQTSGKDECS T516
R617-m1
ERALFTDrMATRSTT
0 1
Wee1 (human) ERALFTDrMATRSTT R617-m1
Wee1 (mouse) ERALFTDRMATRSTT R617
Wee1 (rat) ERALLTDRMATRSTT R617
Wee1 (frog) gap -
S642-p
KKMNRSVsLtIy___
Upstream
Downstream
6 2
Wee1 (human)
S642-p
Wee1 (mouse)
S642-p
Wee1 (rat)
S642-p
Effects on Modified Protein
  • enzymatic activity, inhibited
  • intracellular localization
Kinase, in vitro:
  • BRSK1 iso2 (human)
Putative in vivo kinases:
  • Akt1 (human)
Treatment
  • galiellalactone
  • LY294002
  • resveratrol
Wee1 (human) KKMNRSVsLtIy___ S642-p
Wee1 (mouse) KKMNRSVsLTIY___ S642-p
Wee1 (rat) KKMNRSVSLTIY___ S642
Wee1 (frog) AKNTRSLsFTCGGY_ S549-p
T644-p
MNRSVsLtIy_____
0 8
Wee1 (human) MNRSVsLtIy_____ T644-p
Wee1 (mouse) MNRSVsLTIY_____ T644
Wee1 (rat) MNRSVSLTIY_____ T644
Wee1 (frog) NTRSLsFTCGGY___ T551
Y646-p
RSVsLtIy_______
0 2
Wee1 (human) RSVsLtIy_______ Y646-p
Wee1 (mouse) RSVsLTIY_______ Y646
Wee1 (rat) RSVSLTIY_______ Y646
Wee1 (frog) LsFTCGGY_______ Y555